While registering trademarks for cannabis products at the USPTO is currently impossible, brands are applying creative solutions to the problem, says Leon Steinberg of Dennemeyer.
The evolution of antibody written description standards at the USPTO has put some drug portfolios at risk, say John Heithaus and Gerald Murphy of Birch, Stewart, Kolasch & Birch.
Brazil’s patent law does not allow methods of treatment to be patented, but there are other means of getting protection, according to Kene Gallois and Samantha Salim of Daniel Law.
An upcoming case on the patent eligibility of genetically modified seed in India will have far-reaching ramifications, as Archana Shankar and Gitika Suri of Anand & Anand explain.
It is challenging but not impossible to protect software innovations in Mexico, according to Alejandro Moreno Hernández of Uhthoff, Gomez Vega & Uhthoff.
ACI’s 17th Global Summit on Life Sciences Patents returns to New York on May 15-17, 2019, to provide practical insights on how to maximise your patent term and develop strategies to enhance protections for your patent portfolio.
The 11th annual ChinaBio Partnering Forum global life science partnering event, which will be held on May 8 and 9 in Shanghai, China, is expected to attract more than 1,400 executives from 500-plus life sciences companies spanning an estimated 25 countries.
The 13th annual BIO-Europe Spring 2019 global life science partnering event will be held March 25–27 in Vienna, Austria. Guadalupe Rodriguez and Kit Muller of EBD Group report.
The development of precision treatments must be complemented by the development of precision diagnostics, as Daniel Lim of Kirkland & Ellis explains.
SPCs and trade secrets are just two issues set to be discussed at C5’s 11th Pharma & Biotech Patent Litigation, on February 26 and 27 in Amsterdam. LSIPR reports.